460 related articles for article (PubMed ID: 12036414)
1. Gemcitabine in non-small cell lung cancer.
Crinò L; Cappuzzo F
Expert Opin Pharmacother; 2002 Jun; 3(6):745-53. PubMed ID: 12036414
[TBL] [Abstract][Full Text] [Related]
2. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
[TBL] [Abstract][Full Text] [Related]
3. Update on gemcitabine/carboplatin in patients with advanced non-small cell lung cancer.
Harper P
Semin Oncol; 2003 Aug; 30(4 Suppl 10):2-12. PubMed ID: 12917815
[TBL] [Abstract][Full Text] [Related]
4. Vinorelbine: a review of its use in elderly patients with advanced non-small cell lung cancer.
Curran MP; Plosker GL
Drugs Aging; 2002; 19(9):695-721. PubMed ID: 12381238
[TBL] [Abstract][Full Text] [Related]
5. A phase I/II trial of induction chemotherapy with carboplatin and gemcitabine followed by concurrent vinorelbine and paclitaxel with chest radiation in patients with stage III non-small cell lung cancer.
Argiris A; Liptay M; LaCombe M; Marymont M; Kies MS; Sundaresan S; Masters G
Lung Cancer; 2004 Aug; 45(2):243-53. PubMed ID: 15246197
[TBL] [Abstract][Full Text] [Related]
6. Development of gemcitabine in non-small cell lung cancer: the Italian contribution.
Metro G; Cappuzzo F; Finocchiaro G; Toschi L; Crinò L
Ann Oncol; 2006 May; 17 Suppl 5():v37-46. PubMed ID: 16807461
[TBL] [Abstract][Full Text] [Related]
7. Rationale for non-platinum chemotherapy in advanced NSCLC.
Murren JR
Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):29-34. PubMed ID: 11497229
[TBL] [Abstract][Full Text] [Related]
8. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline.
Chu Q; Vincent M; Logan D; Mackay JA; Evans WK;
Lung Cancer; 2005 Dec; 50(3):355-74. PubMed ID: 16139391
[TBL] [Abstract][Full Text] [Related]
9. Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial.
Niho S; Kubota K; Goto K; Ohmatsu H; Matsumoto T; Kakinuma R; Nishiwaki Y
Cancer Chemother Pharmacol; 2003 Jul; 52(1):19-24. PubMed ID: 12712259
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine-containing regimens vs others in first-line treatment of NSCLC.
Natale RB
Oncology (Williston Park); 2004 Jul; 18(8 Suppl 5):27-31. PubMed ID: 15339056
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine/carboplatin combination regimens: importance of dose schedule.
Gandara DR; Lau DH; Lara PN; Edelman MJ
Oncology (Williston Park); 2000 Jul; 14(7 Suppl 4):26-30. PubMed ID: 10960942
[TBL] [Abstract][Full Text] [Related]
12. Advances in treatment of inoperable NSCLC: gemcitabine doublets--a promising alternative.
Cappuzzo F; Rocha Lima CM; Sherman CA; Green MR
Oncology (Williston Park); 2000 Jul; 14(7 Suppl 4):7-14. PubMed ID: 10960939
[TBL] [Abstract][Full Text] [Related]
13. Triplet chemotherapy with gemcitabine, a platinum, and a third agent in the treatment of advanced non-small cell lung cancer.
Bunn PA
Semin Oncol; 1999 Feb; 26(1 Suppl 4):25-30. PubMed ID: 10201518
[TBL] [Abstract][Full Text] [Related]
14. Does chemotherapy have a role as palliative therapy for unfit or elderly patients with non-small-cell lung cancer?
Gridelli C
Lung Cancer; 2002 Nov; 38 Suppl 2():S45-50. PubMed ID: 12431829
[TBL] [Abstract][Full Text] [Related]
15. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study.
Kubota K; Kawahara M; Ogawara M; Nishiwaki Y; Komuta K; Minato K; Fujita Y; Teramukai S; Fukushima M; Furuse K;
Lancet Oncol; 2008 Dec; 9(12):1135-42. PubMed ID: 19013107
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel (Taxotere) in combination chemotherapy and in association with thoracic radiotherapy for the treatment of non-small-cell lung cancer. Thoracic Oncology Program.
Ornstein DL; Nervi AM; Rigas JR
Ann Oncol; 1999; 10 Suppl 5():S35-40. PubMed ID: 10582137
[TBL] [Abstract][Full Text] [Related]
17. Non-platinum doublets were as effective as platinum-based doublets for chemotherapy-naïve advanced non-small-cell lung cancer in the era of third-generation agents.
Jiang J; Liang X; Zhou X; Huang R; Chu Z; Zhan Q
J Cancer Res Clin Oncol; 2013 Jan; 139(1):25-38. PubMed ID: 22864816
[TBL] [Abstract][Full Text] [Related]
18. Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer.
Mazzanti P; Massacesi C; Rocchi MB; Mattioli R; Lippe P; Trivisonne R; Buzzi F; De Signoribus G; Tuveri G; Rossi G; Di Lullo L; Sturba F; Morale D; Catanzani S; Pilone A; Bonsignori M; Battelli T
Lung Cancer; 2003 Jul; 41(1):81-9. PubMed ID: 12826316
[TBL] [Abstract][Full Text] [Related]
19. Randomized multicentric phase II study of carboplatin/gemcitabine and cisplatin/vinorelbine in advanced non-small cell lung cancer GFPC 99-01 study (Groupe français de pneumo-cancérologie).
Thomas P; Robinet G; Gouva S; Fournel P; Léna H; Le Caer H; Perol M; Berard H; Bombaron P; Vergnenegre A; Kleisbauer JP;
Lung Cancer; 2006 Jan; 51(1):105-14. PubMed ID: 16310886
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of the unresectable non small cell lung carcinoma].
Spásová I
Cas Lek Cesk; 2005; 144(9):602-12; discussion 612-3. PubMed ID: 16193938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
